NCT04272125

Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Chongqing Precision Biotech Co., Ltd · Industry
• Sex: All
• Age: 3 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm study to evaluate the efficacy and safety of CD123-targeted CAR-T cells therapy for patients with relapsed/refractory Acute Myeloid Leukemia.

Detailed description

There are limited options for treatment of relapse/refractory Acute Myeloid Leukemia. CD123 is expressed on most myeloid leukemia cells so it is an ideal target for CAR-T. Some researches have revealed that CD123 is a marker of leukemia stem cells, which indicates that the eradication of CD123 cells may prevent relapse of leukemia. In this study, investigators will evaluate the safety and efficacy of CAR-T targeting CD123 in patients with relapsed/refractory Acute Myeloid Leukemia. The primary goal is safety and efficiency assessment, including adverse events and disease status after treatment.

Conditions

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute

Interventions

Type	Name	Description
BIOLOGICAL	CD123 CAR-T cells	A single infusion of CD123-CAR-T cells will be administered intravenously

Timeline

• Start date: 2019-12-01
• Primary completion: 2023-12-31
• Completion: 2024-07-01
• First posted: 2020-02-17
• Last updated: 2023-04-18

Locations

1 site across 1 country: China